Nanotechnology Applications in Targeted Drug Delivery for Cancer Therapy

Vijay Malhotra^*
*Correspondence: Vijay Malhotra, Department of Nanotechnology, University of Nairobi, Nairobi, Kenya, Email:

Keywords

Nanotechnology • Targeted drug delivery • Cancer therapy • Nanoparticles • Liposomes • Micelles • Personalized medicine • Precision oncology

Introduction

Cancer remains one of the leading causes of mortality worldwide, necessitating the development of innovative therapeutic strategies to improve treatment outcomes and minimize adverse effects. Conventional chemotherapy, while effective in killing cancer cells, often lacks specificity and can cause significant toxicity to healthy tissues, leading to systemic side effects and treatment-related complications [1]. Targeted drug delivery systems have emerged as a promising approach for enhancing the efficacy and safety of cancer therapy by selectively delivering therapeutic agents to tumor sites while sparing normal tissues.

Nanotechnology, the manipulation of materials at the nanoscale, offers unique opportunities for targeted drug delivery in cancer therapy. Nanoparticles, liposomes, micelles and other nanostructures possess distinct physicochemical properties, such as size, shape, surface charge and biocompatibility, which make them suitable candidates for drug encapsulation, targeting and controlled release [2]. By exploiting these properties, nanotechnology enables the design of multifunctional nanocarriers capable of overcoming biological barriers, evading immune surveillance and enhancing therapeutic efficacy against cancer.

Literature Review

Nanoparticles, such as polymeric nanoparticles, lipid nanoparticles and inorganic nanoparticles, are versatile drug delivery vehicles that can encapsulate a wide range of anticancer agents, including chemotherapeutic drugs, nucleic acid-based therapeutics and targeted biologics. These nanoparticles offer several advantages, including high drug loading capacity, sustained release kinetics and protection of drugs from enzymatic degradation and premature clearance. Surface modification of nanoparticles with targeting ligands, such as antibodies, peptides and aptamers, enables selective binding to tumor-specific antigens or receptors, enhancing tumor accumulation and cellular uptake while minimizing off-target effects.

Liposomes are lipid-based vesicles composed of phospholipid bilayers that can encapsulate hydrophilic and hydrophobic drugs within their aqueous core and lipid membrane, respectively. Liposomal formulations, such as Doxil® and Myocet®, have been approved for the treatment of various cancers, including breast cancer, ovarian cancer and Kaposi's sarcoma [3]. Liposomes offer advantages such as prolonged circulation time, reduced systemic toxicity and enhanced tumor accumulation through the enhanced permeability and retention (EPR) effect. Surface modification of liposomes with polyethylene glycol (PEGylation) further improves their stability, circulation half-life and tumor targeting efficiency.

Micelles are self-assembled nanostructures composed of amphiphilic block copolymers that can encapsulate hydrophobic drugs within their core and shield them from aqueous environments. Micellar formulations, such as Abraxane® and Genexol-PM®, have been approved for the treatment of various cancers, including breast cancer, pancreatic cancer and lung cancer. Micelles offer advantages such as improved solubility, bioavailability and tumor penetration, enabling effective delivery of poorly soluble drugs to tumor sites. Surface modification of micelles with targeting ligands or stimuli-responsive materials allows for enhanced tumor targeting and controlled drug release in response to specific stimuli, such as pH, temperature, or enzymes.

Discussion

Other nanostructures, such as dendrimers, carbon nanotubes and mesoporous silica nanoparticles, have also been explored for targeted drug delivery in cancer therapy. Dendrimers are highly branched polymers with well-defined structures and surface functionalities that can encapsulate drugs within their interior and bind targeting ligands to their surface. Carbon nanotubes are cylindrical nanostructures composed of carbon atoms arranged in a hexagonal lattice that can serve as carriers for drug delivery and imaging agents for cancer diagnosis [4]. Mesoporous silica nanoparticles are porous materials with high surface area and tunable pore sizes that can encapsulate drugs within their pores and release them in a controlled manner.

In addition to drug delivery, nanotechnology offers opportunities for realtime monitoring of therapeutic responses and disease progression through the development of multifunctional nanoprobes and imaging agents. Nanoparticles functionalized with imaging moieties, such as fluorescent dyes, magnetic nanoparticles, or radioactive tracers, enable non-invasive visualization of tumors, assessment of drug distribution and monitoring of treatment responses in vivo. These imaging technologies facilitate early detection of tumors, evaluation of treatment efficacy and optimization of therapeutic regimens, paving the way for personalized medicine approaches in cancer therapy.

Despite the promise of nanotechnology in targeted drug delivery for cancer therapy, several challenges remain in clinical translation and scale-up. Issues such as batch-to-batch variability, reproducibility and manufacturing scalability pose challenges to the production of nanomedicines on a large scale. Moreover, concerns regarding safety, biocompatibility and long-term toxicity of nanomaterials require comprehensive preclinical evaluation and regulatory oversight to ensure patient safety [5,6]. Additionally, the heterogeneity of tumors, interpatient variability and tumor microenvironmental factors can impact the efficacy and responsiveness of nanotherapeutics, necessitating personalized treatment strategies tailored to individual patient characteristics.

Conclusion

In conclusion, nanotechnology holds immense promise for targeted drug delivery in cancer therapy, offering opportunities to enhance treatment efficacy, reduce systemic toxicity and overcome drug resistance. Nanoparticles, liposomes, micelles and other nanostructures enable precise control over drug delivery, biodistribution and release kinetics, thereby improving the therapeutic index of anticancer agents. By incorporating targeting ligands, imaging agents and stimuli-responsive materials, nanotechnology facilitates site-specific drug delivery, real-time monitoring of therapeutic responses and personalized treatment approaches in cancer therapy. Despite challenges in clinical translation and scale-up, ongoing research efforts and technological advancements in nanomedicine are driving progress towards more effective, personalized and precision oncology approaches that hold the potential to revolutionize cancer treatment and improve patient outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Bashiri, Ghazal, Marshall S. Padilla, Kelsey L. Swingle and Sarah J. Shepherd, et al. "Nanoparticle protein corona: from structure and function to therapeutic targeting."Lab Chip23 (2023): 1432-1466.

   Google Scholar, Crossref, Indexed at

2. Breznica, Pranvera, Rozafa Koliqi and Arlinda Daka. "A review of the current understanding of nanoparticles protein corona composition."Med Pharm Rep 93 (2020): 342.

   Google Scholar, Crossref, Indexed at

3. Tomak, Aysel, Selin Cesmeli, Bercem D. Hanoglu and David Winkler, et al. "Nanoparticle-protein corona complex: understanding multiple interactions between environmental factors, corona formation and biological activity."Nanotoxicology15 (2021): 1331-1357.

   Google Scholar, Crossref, Indexed at

4. Geppert, Mark and Martin Himly. "Iron oxide nanoparticles in bioimaging–an immune perspective."Front Immunol 12 (2021): 688927.

   Google Scholar, Crossref, Indexed at

5. Norouzi, Mohammad, Vinith Yathindranath, James A. Thliveris and Brian M. Kopec, et al. "Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: A combinational approach for enhanced delivery of nanoparticles."Sci Rep 10 (2020): 11292.

   Google Scholar, Crossref, Indexed at

6. Liu, Jing, Songzheng Zhao and Xiaodi Zhang. "An ensemble method for extracting adverse drug events from social media."Artif Intell Med 70 (2016): 62-76.

   Google Scholar, Crossref, Indexed at